Pretreatment Serum Lactate Dehydrogenase Predicting Metastatic Spread in Ewing's Sarcoma

  1. HARMAR D. BRERETON, M.D.;
  2. RICHARD SIMON, Ph.D.; and
  3. THOMAS C. POMEROY, M.D.
  1. Bethesda, Maryland

    Abstract

    We measured serum lactate dehydrogenase levels in 36 patients with localized Ewing's sarcoma before treatment. The results were evaluated to determine if the levels served as a prognostic indicator for metastatic spread. After adjusting for primary site of disease and adjuvant chemotherapy, the pretreatment serum lactate dehydrogenase proved an extremely good predictor of which patients would ultimately develop metastatic disease. The median serum lactate dehydrogenase of the total group was between 201 and 214 IU/litre. Three of 18 patients presenting with serum levels of this enzyme of ≤ 201 IU/litre ultimately developed metastases, while 16 of 18 patients who presented with serum levels of ≥ 214 IU/litre developed metastases (P < 0.001).

    Article and Author Information

    • ▸From the Radiation Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.

    • ▸Requests for reprints should be addressed to Harmar D. Brereton, M.D., Clinical Center, Bldg. 10, Room B3B38, National Institutes of Health, Bethesda, MD 20014.

    « Previous | Next Article »Table of Contents

    This Article

    1. Ann Intern Med September 1, 1975 vol. 83 no. 3 352-354
    1. » Abstract
    2. Full Text (PDF)

    Rapid Responses

    1. Submit a response
    2. No responses published

    Current Issue

    1. December 1, 2009, 151 (11)
    1. Alert me to current issues